The effect of menaquinone-7 supplementation on dp-ucMGP, PIVKAII, inflammatory markers, and body composition in type 2 diabetes patients: a randomized clinical trial.
- 2022-04-01
- RCT · n = 45
- Nutrition & diabetes 12(1)
- Nahid Karamzad
- Esmaeil Faraji
- Shaghayegh Adeli
- Mark J M Sullman
- Bahram Pourghassem Gargari
- PubMed: 35365594
- DOI: 10.1038/s41387-022-00192-5
- High evidence
- Clinical
Following the intervention, the serum levels of the inflammatory markers (hsCRP, IL-6, and TNF-α) were significantly lower in the MK-7 group (p < 0.05), but not in the placebo group. However, the between group differences in the inflammatory markers were not statistically significant.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 200 mcg/day